Project ECHO: Methadone in the Age of Fentanyl
August 8 – Cara Zimmerman, MD, MBA | Transition in Methadone and Buprenorphine
September 12 – David Kispert, MD | Methadone in the Age of Fentanyl
October 10 – Stephanie Nichols, PharmD, BCPP, MPH | Drug Interactions with Methadone
November 14 – Alane O’Connor DNP | Methadone and Pregnant People
December 12 – Jacquelyn Cyr, FNP | Regulations of Methadone
January 9 – Cara Zimmerman, MD, MBA | Pain and Methadone
Learning Objectives:
- Explore the role of Methadone in MOUD
- Identify where Methadone fits into the continuum of care in MOUD
- Understand the role of transitions in the employment MOUD medication
Description
Of the roughly 2.1 million U.S. adults who have opioid use disorder, 19% receive Methadone treatment. In the current illicit drug supply landscape, Methadone and other MOUD medications are a vital part of preventing overdose harm and deaths and supporting recovery. This 6-month Project ECHO will highlight Methadone as a treatment for Opioid Use Disorder, with a focus on state-of-the-art practices and treatments.
Speaker
-
Cara Zimmerman MD MBACara Zimmerman, MD, MBA, is the Medical Director of Primary Care-Based Substance Use Disorder Treatment (MAT/OBAT) at Thundermist Health Center. She completed her Addiction Medicine and Internal Medicine training at Brown University and is a Clinical Assistant Professor of Medicine at Brown University. She is a staunch advocate for harm reduction in her primary care and addiction practice and is interested in quality improvement and systems processes, nontraditional forms of care delivery such as street medicine, and behavior change. She is also the Chairman of the Board of Directors of the leading harm reduction organization in the state, Project Weber/RENEW. She consults as part of the Opioid Response Network to teach colleagues about substance use disorder and loves being part of a multidisciplinary team.
